AB Science SA

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

07 Jan 2026 12:03:03 By Nasdaq GlobeNewswire

AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040

22 Dec 2025 11:57:55 By Nasdaq GlobeNewswire

AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

18 Dec 2025 13:17:24 By Nasdaq GlobeNewswire

AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

15 Dec 2025 12:39:28 By Nasdaq GlobeNewswire

AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function

11 Dec 2025 12:29:10 By Nasdaq GlobeNewswire

AB Science announces the successful completion of a EUR 2.8 million private placement

17 Oct 2025 02:00:23 By Nasdaq GlobeNewswire

AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

16 Oct 2025 14:57:48 By Nasdaq GlobeNewswire

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939

14 Oct 2025 02:36:15 By Nasdaq GlobeNewswire

AB Science today reports its revenues for the first half of 2025 and provides an update on its activities

10 Oct 2025 12:10:16 By Nasdaq GlobeNewswire

AB Science announces a slight delay in the publication of its 2025 half-year financial report

30 Sep 2025 12:32:42 By Nasdaq GlobeNewswire

AB Science announces the successful completion of a 2.55 million euros private placement

04 Aug 2025 01:58:35 By Nasdaq GlobeNewswire

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML

30 Jul 2025 01:45:48 By Nasdaq GlobeNewswire

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS

24 Jul 2025 01:57:04 By Nasdaq GlobeNewswire

AB Science announces the successful completion of a EUR 1.925 million private placement

08 Jul 2025 02:01:55 By Nasdaq GlobeNewswire

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

04 Jul 2025 02:01:23 By Nasdaq GlobeNewswire

AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors

30 Jun 2025 02:03:29 By Nasdaq GlobeNewswire

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease

23 Jun 2025 02:03:15 By Nasdaq GlobeNewswire

AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036

12 Jun 2025 01:59:17 By Nasdaq GlobeNewswire

AB Science announces EMA approval of Masivet shelf-life extension to 4 years

09 Jun 2025 02:01:20 By Nasdaq GlobeNewswire

AB Science announces the settlement delivery of its latest capital increase for €1.8 million

23 May 2025 01:52:26 By Nasdaq GlobeNewswire